Login
No login? Register now to unlock hella tokens
No login? Register now to unlock hella tokens
Log In person
Neuren Pharmaceuticals Ltd
summarize 3 total product lines
calendar_month Revenue as of 12/31/2023
Reporting Segmentarrow_drop_up Product Line Amount (AUD) Percentage
keyboard_arrow_right Reporting Segment & Product Line Amount (AUD) Percentage
Commercial Products
Branded Pharmaceuticals (outsourced)
These companies research, develop, and outsource the manufacturing of patented drugs.
205.15M 88.45%
Commercial Products
Pharmaceutical Patent Licensing
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
26.78M 11.55%
Research & Development
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
Non-Attributed
Non-Attributed help Why Zero? Explanation of what the heck's going on here.
keyboard_arrow_right keyboard_arrow_down
Commercial Products
Branded Pharmaceuticals (outsourced)
205.15M 88.45%
keyboard_arrow_right
These companies research, develop, and outsource the manufacturing of patented drugs.
keyboard_arrow_right keyboard_arrow_down
Commercial Products
Pharmaceutical Patent Licensing
26.78M 11.55%
keyboard_arrow_right
These companies collect royalties from pharma and biotech companies who make biotech products they developed or products that incorporate their technologies.
keyboard_arrow_right keyboard_arrow_down
Research & Development
Pre-Revenue Pharmaceuticals
Non-Attributed
Non-Attributed help Why Zero? Explanation of what the heck's going on here.
keyboard_arrow_right
help Why Zero? Explanation of what the heck's going on here.
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.